Regarding adiponectin, there are very few scientific data evaluating the relationship between the level of adiponectin and the anti-tumor drug efficacy or treatment resistance, except in a clinical study published in 2012 by Macis and colleagues where it was shown that there was no interaction between treatment and adiponectin levels in 235 premenopausal women with breast cancer taking low-dose tamoxifen and fenretinide [91]. The gene discussed is ADIPOQ; the disease is breast carcinoma.